z-logo
open-access-imgOpen Access
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Author(s) -
Kim A. Connelly,
C. David Mazer,
Pankaj Puar,
Hwee Teoh,
ChaoHung Wang,
Tamique Mason,
Farhad Akhavein,
ChingWen Chang,
MinHui Liu,
NingI Yang,
Wei-Siang Chen,
YuHsiang Juan,
Erika Opingari,
Yaseen Salyani,
William Barbour,
Aryan Pasricha,
Shamon Ahmed,
Andrew Kosmopoulos,
Raj Verma,
Michael Moroney,
Ehab Bakbak,
Aishwarya Krishnaraj,
Deepak L. Bhatt,
Javed Butler,
Mikhail Kosiborod,
Carolyn S.P. Lam,
David A. Hess,
Otávio R. CoelhoFilho,
Myriam LafrenièreRoula,
Kevin E. Thorpe,
Adrian Quan,
Lawrence A. Leiter,
Andrew T. Yan,
Subodh Verma
Publication year - 2022
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.122.062769
Subject(s) - empagliflozin , medicine , heart failure , cardiology , ejection fraction , diabetes mellitus , placebo , interquartile range , type 2 diabetes , endocrinology , alternative medicine , pathology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom